Delivery Order SPE2DB22D1200-SPE2DB25FN2FZ
- Not listed
- The Defense Logistics Agency awarded a $6,392.26 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for Zepbound 7.5 mg/0.5 ml pen injections. This contract represents a firm fixed price delivery order with an ultimate completion date of June 3, 2025, and was awarded through open competition without set-aside designation. The award is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $16,124.42 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This competitively awarded, firm fixed price contract carries an ultimate completion date of July 21, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $3,431.61 on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price, non-set-aside delivery order is scheduled for completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's larger relationship...
- The Defense Logistics Agency awarded a delivery order valued at $6,518.07 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order executed under an existing contract vehicle and requires fulfillment within an...
- The Defense Logistics Agency awarded a $27,216.21 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injections, with an ultimate completion date of September 22, 2025. This non-set-aside delivery order was competitively awarded and represents a single transaction under AmerisourceBergen's existing contract vehicles supporting federal pharmaceutical procurement. The product will be delivered to the company's Conshohocken, Pennsylvania facility, where...
- The Defense Logistics Agency awarded a delivery order valued at $2,178.52 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on June 24, 2025, with completion targeted for June 25, 2025. This competitively awarded, firm fixed-price delivery order represents fulfillment under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $9,927.33 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical supplier to the federal government. The order will be fulfilled from the contractor's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $7,135.59 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 6, 2025, with completion targeted for August 7, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitive award to the pharmaceutical distributor for medical supplies supporting federal healthcare needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill...
- The Defense Logistics Agency awarded a delivery order valued at $6,148.98 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price contract with no set-aside designation, classified as a competitive delivery order under the company's broader pharmaceutical supply agreements. Performance will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14,...
- The Defense Logistics Agency awarded a delivery order valued at $23,545.58 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 16, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN2FZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections valued at $9,805.19 on May 30, 2025, with completion scheduled for June 2, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement supporting federal medical supply needs. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle provides comprehensive pharmaceutical support globally, enabling the company to supply a wide range of medications and medical supplies to military healthcare systems, the Defense Health Agency, and other federal healthcare entities. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive portfolio of federal contracts for brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains, demonstrating its capability to meet diverse federal procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.8k | 5/30/25 |